Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celgene International Sarl has announced positive preliminary data from an international study of single agent Revlimid in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Subscribe to our email newsletter
In this study of heavily pretreated patients, 83 were eligible for response evaluation. An objective response was observed in 29% of patients, with 6% achieving a complete response (CR/CRu), 23% achieving a partial response and 19% showing stable disease.
According to non-Hodgkin’s lymphoma (NHL) histology, objective response was 36% in mantle cell lymphoma, 22% in diffuse large b-cell lymphoma, 33% in follicular lymphoma (grade three) and 50% in transformed lymphoma. These responses included several patients that had been refractory to their prior therapies, including rituxamab based regimens.
Myron Czuczman, head of lymphoma/myeloma section for department of medicine at Roswell Park Cancer Institute, said: “These data demonstrate that lenalidomide has activity in relapsed/refractory aggressive NHL with a favorable safety profile. Early results from this large international study appear to confirm the results obtained from a previous, smaller, US-based Phase II study.”